The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Breaking barriers: Upfront expense payments to ease the economic burden for clinical trial patients.
 
Chiara Martinelli
Employment - F. Hoffmann LaRoche
 
Lyra del Rosario
No Relationships to Disclose
 
Jennifer Ball
Employment - F. Hoffmann LaRoche
 
Ruth Davies
Employment - F. Hoffmann LaRoche
 
Angelina McLeod
Employment - F. Hoffmann LaRoche
 
Jose Manuel Ordonez
Employment - F. Hoffmann LaRoche
 
Cristina Ramon
Employment - F. Hoffmann LaRoche
 
Johann De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Acai Therapeutics; Amgen; Amunix (Inst); Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); AstraZeneca (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); MorphoSys (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi
 
Markella Boudioni
No Relationships to Disclose
 
Jennifer Lauman
No Relationships to Disclose
 
Adam Sharp
No Relationships to Disclose
 
Mary Van Zyl
No Relationships to Disclose
 
Ana Matres Rojo
No Relationships to Disclose
 
Cristina Perez
No Relationships to Disclose
 
Laura Arribillaga
No Relationships to Disclose
 
Gabriel Canel
No Relationships to Disclose
 
Maria Luisa Bezares
No Relationships to Disclose
 
Maria Lapuente
No Relationships to Disclose
 
Eric Mackelprang
Employment - Greenphire
 
Bindumalini Rao Baikady
No Relationships to Disclose